Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glutamine Supplementation in Immune Dysregulation
NCT04019769Phase 1Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2020
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glutamine in atopic dermatitis (AD) and immune dysregulation, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Safety and Tolerability of Glutamine Supplementation at 1 year. Planned start Mar 2020; status: withdrawn.
02
Drugs
glutamine
03
Conditions
atopic dermatitis (AD)immune dysregulation
Beyond the preview
Go deeper on NCT04019769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04019769.